We further show that pharmacological activation of FXR by hammerhead-type agonists induces a liver-specific enhancer-derived lncRNA, which we named Fincor, that contributes to reduction of NASH pathologies in mice. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.